Shanghai Bao Pharmaceuticals Co Ltd

The company's capital structure is characterized by a high level of liquidity, with cash and equivalents amounting to CNY 1.24 billion, which is significantly higher than its total liabilities of CNY 625 million. The liquidity ratio of 4.12 indicates a strong ability to meet short-term obligations. However, the company is experiencing negative operating and net income, with operating income at CNY -389 million and net income at CNY -395 million. The price-to-book ratio of 5.54 suggests that the market is valuing the company at a premium relative to its book value, despite its current financial performance. Profitability metrics are notably weak, with a return on equity of -24.83% and a return on assets of -17.83%. These figures are below the industry median for biotechnology firms, which typically exhibit positive returns during periods of growth and innovation. The company's gross profit margin is 89.0%, which is relatively high, but this is offset by significant operating and net losses. The company's debt-to-equity ratio of 0.2 indicates a conservative capital structure, with limited leverage. Geographically and segment-wise, the company's revenue is not disclosed by region or business segment in the available data. However, the company's operations are primarily based in China, and its exposure to the domestic market is likely significant. The lack of segmental breakdown limits the ability to assess diversification and concentration risk. The company's growth trajectory is currently negative, with a revenue of CNY 491.56 million in the latest period. Analysts have provided a mean price target of CNY 111.30, which is significantly higher than the current market price of CNY 27.04, suggesting a potential for future growth. However, the company's operating cash flow is negative at CNY -180 million, and free cash flow is also negative at CNY -511.52 million, indicating that the company is not generating sufficient cash from operations to sustain or grow its business. Risk factors include the company's negative net income and operating cash flow, which could impact its ability to fund operations and invest in growth. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative free cash flow and operating cash flow suggest potential liquidity constraints in the future. The company has not issued any recent dilutive events, and the dilution potential is currently low. Recent events include the publication of the latest financial data, which shows a significant operating and net loss. There are no recent filings or transcripts indicating major strategic shifts or operational changes. The company's capital expenditure of CNY -153.36 million suggests ongoing investment in infrastructure or research, but the negative value indicates a cash outflow.